Sleep

The Morning After: Sleeping Pills and Driving

Save

Feeling rested the morning after a sleeping pill is not the same as being unimpaired behind the wheel. Regulators have found otherwise for some of the most commonly prescribed hypnotics. Here is what the evidence shows about next-day driving risk, who it affects most, and how to reduce it.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Can You Drive the Morning After Taking a Sleeping Pill?

It depends on the specific drug, not on how awake a person feels. Some hypnotics clear the body slowly enough that a next-morning blood level can still impair reaction time, attention, and lane control, even when the person taking it reports feeling normal. Residual sedation is the term for this gap between subjective alertness and actual impairment, and it is exactly what regulators have found with some of the most widely prescribed sleep medications.

This is not a reason to assume every sleep medication carries the same risk. It is a reason to ask specifically about the one that was prescribed, rather than generalizing from a friend's experience with a different drug.

Why Zolpidem Got a Specific Next-Morning Warning

In 2013, the FDA required lower recommended zolpidem doses after research found that next-morning blood levels remained high enough in some patients — particularly women, who clear the drug more slowly — to impair driving-related skills, even among people who felt fully awake 1. That finding came from blood-level and simulated-driving data, not from self-reported grogginess, which is exactly why it changed prescribing guidance: the people at risk often could not tell from how they felt.

The warning applies specifically to zolpidem-containing products. It is a useful example of how residual sedation gets identified, but it does not automatically describe every hypnotic on the market.

It's Not Just One Drug: The Z-Drugs as a Class

The z-drugs — zolpidem, eszopiclone, and zaleplon — share more than a nickname. In 2019 the FDA added a boxed warning across the class for rare but serious injuries and deaths linked to complex sleep behaviors like sleepwalking and sleep-driving, behaviors a person can engage in with no memory of them afterward, occurring even after a single dose 2. Driving is the most literal version of this risk: a person who does not remember getting behind the wheel cannot judge their own fitness to be there.

For a fuller look at what these z-drugs are and how they differ from one another, the broader picture matters as much as any single warning label.

Who Is at Highest Risk for Next-Day Impairment?

Sex-based differences in drug clearance are the clearest documented risk factor, which is why the zolpidem dose guidance specifically singled out women 1. Age compounds the risk further: slower drug metabolism generally accompanies aging, and sleeping pill risks in older adults already include a higher chance of next-day sedation stacking with reduced coordination and reaction time.

Combining a hypnotic with alcohol or another sedative, or taking it later at night than intended with an early wake time to follow, both extend the window in which blood levels can remain high enough to matter. None of these factors are visible from how alert a person feels in the morning.

What About Trazodone or Other Off-Label Options?

Trazodone, used off-label for insomnia at low doses, has a systematic review behind it showing modest, if low-quality, evidence for improved sleep continuity 3. What it does not have is a comparable body of next-morning driving-impairment research the way zolpidem does — not necessarily because it is safer, but because it has not been studied for this specific question with the same regulatory scrutiny.

That gap cuts against assuming any off-label sedating option is automatically a safer bet for next-day driving than a drug with a known warning. A known risk with data behind it is, in a real sense, more informative than an unknown one.

Medication classNext-morning driving data
Zolpidem and other z-drugsFDA-reviewed blood-level and simulated-driving findings; boxed warning for complex sleep behaviors
Off-label sedating antidepressants (e.g., trazodone)Modest sleep-continuity evidence; no comparable next-morning driving research in this record

Reducing the Risk Without Guessing

The clearest lever is timing: the FDA's own findings on zolpidem were about blood levels that were still elevated the next morning, which points toward leaving as much time as possible between a dose and an expected drive 1. Avoiding alcohol or other sedatives on a night a hypnotic is taken removes one of the more controllable risk multipliers.

For anyone reconsidering a hypnotic altogether, cognitive behavioral therapy for insomnia produced better durable results than the z-drug zopiclone in a randomized trial, without any of this next-day impairment question attached 4. Tapering hypnotics under a clinician's guidance, rather than stopping abruptly, also avoids trading a driving risk for a rebound-insomnia problem instead.

The Conversation Worth Having With a Prescriber

Reporting exactly how a hypnotic feels the next morning — foggy, clear-headed, somewhere in between — gives a prescriber real information to work with, more useful than guessing at a dose adjustment alone. A guideline on deprescribing benzodiazepine receptor agonists specifically recommends clinicians offer a taper when harms like these are in play, rather than leaving the decision unaddressed indefinitely 5.

That conversation is also the right place to ask whether an occasional early-morning obligation, like a long drive, calls for skipping a dose entirely rather than adjusting the routine long-term.

Common questions

It depends on the person, but the FDA found that some people, especially women, have blood levels the next morning high enough to impair driving even when they feel fully awake. That finding is specifically why recommended zolpidem doses were lowered in 2013.

No. The clearest documented next-morning driving risk applies to the z-drugs, especially zolpidem. Other options, like off-label trazodone, don't have the same body of driving-specific research, which reflects a research gap more than a proven safety difference.

Subjective alertness is not a reliable indicator — that's the core finding behind the zolpidem warning. People who felt fully awake still tested with blood levels high enough to affect reaction time, which is why the guidance focuses on timing and dose rather than how a person feels.

It reduces the risk for many people but does not eliminate it for everyone, since clearance varies by sex, age, and individual metabolism. The right dose and timing for a given person is a decision for the prescribing clinician, not something to adjust independently.

Leaving as much time as possible between the dose and an expected drive, avoiding alcohol or other sedatives that night, and reporting any next-morning fogginess to the prescriber all help. For some people, switching to a behavioral approach like CBT-I removes the question entirely.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

If things feel heavy, a person is available anytime — call or text 988.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When This Is More Than a Grogginess Question

  • —any accident, near-miss, or memory gap involving driving after taking a sleep medication
  • —sleepwalking, sleep-driving, or other activity with no memory of it afterward
  • —persistent grogginess, dizziness, or slowed reaction time well into the next day
  • —combining a sleep medication with alcohol or another sedative before an expected early wake time

Any injury, or an accident linked to sleep-driving or next-day impairment, is a medical emergency: call 911 or go to the nearest emergency room. Report any sleepwalking or sleep-driving episode to the prescribing clinician right away, even if no one was hurt.

This page explains general evidence and does not replace individualized medical advice. Any change to a prescribed sleep medication should go through the clinician who prescribed it.

References

  1. 1.US Food and Drug Administration (2013). Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). FDA Drug Safety Communication. link ✓FDA lowered recommended zolpidem doses after finding next-morning blood levels, especially in women, high enough to impair driving.
  2. 2.US Food and Drug Administration (2019). Certain Prescription Insomnia Medicines: New Boxed Warning — Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake. FDA Drug Safety Communication. link ✓Boxed warning for eszopiclone, zaleplon, and zolpidem for complex sleep behaviors including sleep-driving, occurring even after a single dose.
  3. 3.Jaffer KY, Chang T, Vanle B, et al. (2017). Trazodone for Insomnia: A Systematic Review. Innovations in Clinical Neuroscience. link ✓Trazodone is used off-label for insomnia with modest, low-quality evidence of benefit on sleep continuity.
  4. 4.Sivertsen B, Omvik S, Pallesen S, et al. (2006). Cognitive Behavioral Therapy vs Zopiclone for Treatment of Chronic Primary Insomnia in Older Adults: A Randomized Controlled Trial. JAMA. doi:10.1001/jama.295.24.2851 ✓CBT-I produced better durable sleep efficiency than the z-drug zopiclone at six months.
  5. 5.Pottie K, Thompson W, Davies S, et al. (2018). Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Canadian Family Physician. linkRecommends clinicians offer a taper for benzodiazepines and z-drugs used for insomnia given harms.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library